Rajmohan Murali Mbbs,, Frcpa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/951525/publications.pdf

Version: 2024-02-01

195 papers 13,324 citations

59 h-index 24982 109 g-index

199 all docs 199 docs citations

199 times ranked 17725 citing authors

#	Article	IF	CITATIONS
1	Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade. Cell, 2013, 155, 1309-1322.	28.9	801
2	Tumor-Infiltrating Lymphocyte Grade Is an Independent Predictor of Sentinel Lymph Node Status and Survival in Patients With Cutaneous Melanoma. Journal of Clinical Oncology, 2012, 30, 2678-2683.	1.6	691
3	Germline mutations in BAP1 predispose to melanocytic tumors. Nature Genetics, 2011, 43, 1018-1021.	21.4	662
4	HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature, 2018, 554, 189-194.	27.8	572
5	Kinase fusions are frequent in Spitz tumours and spitzoid melanomas. Nature Communications, 2014, 5, 3116.	12.8	521
6	Classification of endometrial carcinoma: more than two types. Lancet Oncology, The, 2014, 15, e268-e278.	10.7	479
7	Copy number alteration burden predicts prostate cancer relapse. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 11139-11144.	7.1	299
8	A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nature Genetics, 2013, 45, 1226-1231.	21.4	270
9	A Distinct Subset of Atypical Spitz Tumors is Characterized by BRAF Mutation and Loss of BAP1 Expression. American Journal of Surgical Pathology, 2012, 36, 818-830.	3.7	264
10	Tumours associated with BAP1 mutations. Pathology, 2013, 45, 116-126.	0.6	242
11	Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway. Nature Genetics, 2015, 47, 1194-1199.	21.4	221
12	Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death. ELife, 2018, 7, .	6.0	217
13	TERT Promoter Mutation Status as an Independent Prognostic Factor in Cutaneous Melanoma. Journal of the National Cancer Institute, 2014, 106, .	6.3	204
14	Diverse <i>BRCA1</i> and <i>BRCA2</i> Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer. Clinical Cancer Research, 2017, 23, 6708-6720.	7.0	194
15	Alternative transcription initiation leads to expression of a novel ALK isoform in cancer. Nature, 2015, 526, 453-457.	27.8	191
16	Conjunctival Melanomas Harbor <i>BRAF</i> and <i>NRAS</i> Mutations and Copy Number Changes Similar to Cutaneous and Mucosal Melanomas. Clinical Cancer Research, 2013, 19, 3143-3152.	7.0	187
17	<i>BRAF</i> mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site. Pigment Cell and Melanoma Research, 2011, 24, 345-351.	3.3	180
18	Comprehensive Study of the Clinical Phenotype of Germline <i>BAP1</i> Variant-Carrying Families Worldwide. Journal of the National Cancer Institute, 2018, 110, 1328-1341.	6.3	164

#	Article	IF	CITATIONS
19	High-grade Endometrial Carcinomas: Morphologic and Immunohistochemical Features, Diagnostic Challenges and Recommendations. International Journal of Gynecological Pathology, 2019, 38, S40-S63.	1.4	164
20	Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 10995-11000.	7.1	146
21	Squamous precursor lesions of the vulva: current classification and diagnostic challenges. Pathology, 2016, 48, 291-302.	0.6	146
22	Genomic aberrations in spitzoid melanocytic tumours and their implications for diagnosis, prognosis and therapy. Pathology, 2016, 48, 113-131.	0.6	145
23	Blue Nevi and Related Lesions. Advances in Anatomic Pathology, 2009, 16, 365-382.	4. 3	141
24	TFE3 Translocation–associated Perivascular Epithelioid Cell Neoplasm (PEComa) of the Gynecologic Tract. American Journal of Surgical Pathology, 2015, 39, 394-404.	3.7	140
25	Desmoplastic neurotropic melanoma. Cancer, 2008, 113, 2770-2778.	4.1	131
26	ZC3H7B-BCOR high-grade endometrial stromal sarcomas: a report of 17 cases of a newly defined entity. Modern Pathology, 2018, 31, 674-684.	5. 5	130
27	The prognostic significance of sentinel node tumour burden in melanoma patients: An international, multicenter study of 1539 sentinel node-positive melanoma patients. European Journal of Cancer, 2014, 50, 111-120.	2.8	127
28	Sentinel Lymph Node Biopsy in Histologically Ambiguous Melanocytic Tumors With Spitzoid Features (So-Called Atypical Spitzoid Tumors). Annals of Surgical Oncology, 2008, 15, 302-309.	1.5	116
29	Non-Sentinel Node Risk Score (N-SNORE): A Scoring System for Accurately Stratifying Risk of Non-Sentinel Node Positivity in Patients With Cutaneous Melanoma With Positive Sentinel Lymph Nodes. Journal of Clinical Oncology, 2010, 28, 4441-4449.	1.6	111
30	Pigmented Epithelioid Melanocytoma: Favorable Outcome After 5-year Follow-up. American Journal of Surgical Pathology, 2009, 33, 1778-1782.	3.7	110
31	Prognostic factors in cutaneous desmoplastic melanoma. Cancer, 2010, 116, 4130-4138.	4.1	109
32	TERT promoter mutations are frequent in atypical fibroxanthomas and pleomorphic dermal sarcomas. Modern Pathology, 2014, 27, 502-508.	5 . 5	108
33	Sentinel Lymph Node Biopsy in Patients With Thin Primary Cutaneous Melanoma. Annals of Surgery, 2012, 255, 128-133.	4.2	103
34	Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathway. Oncotarget, 2015, 6, 36041-36052.	1.8	103
35	Pathologic examination of sentinel lymph nodes from melanoma patients. Seminars in Diagnostic Pathology, 2008, 25, 100-111.	1.5	102
36	Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Design, Development and Therapy, 2012, 6, 391.	4.3	102

#	Article	IF	Citations
37	Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer. Clinical Cancer Research, 2018, 24, 5939-5947.	7.0	100
38	Toward an Improved Definition of the Tumor Spectrum Associated With <i>BAP1</i> Germline Mutations. Journal of Clinical Oncology, 2012, 30, e337-e340.	1.6	99
39	Epigenome-wide DNA methylation landscape of melanoma progression to brain metastasis reveals aberrations on homeobox D cluster associated with prognosis. Human Molecular Genetics, 2014, 23, 226-238.	2.9	96
40	Atypical Spitzoid Melanocytic Tumors With Positive Sentinel Lymph Nodes in Children and Teenagers, and Comparison With Histologically Unambiguous and Lethal Melanomas. American Journal of Surgical Pathology, 2009, 33, 1386-1395.	3.7	95
41	The prognostic and staging implications of bone invasion in oral squamous cell carcinoma. Cancer, 2011, 117, 4460-4467.	4.1	95
42	Diagnosis of cutaneous melanocytic tumours by four-colour fluorescence in situ hybridisation. Pathology, 2009, 41, 383-387.	0.6	92
43	SF3B1 and BAP1 mutations in blue nevus-like melanoma. Modern Pathology, 2017, 30, 928-939.	5.5	81
44	Genetic and clinico-pathologic analysis of metastatic uveal melanoma. Modern Pathology, 2014, 27, 175-183.	5 . 5	78
45	TERT Promoter Mutations Are Frequent in Cutaneous Basal Cell Carcinoma and Squamous Cell Carcinoma. PLoS ONE, 2013, 8, e80354.	2.5	78
46	Carcinoid Tumors of the Urinary Tract and Prostate. Archives of Pathology and Laboratory Medicine, 2006, 130, 1693-1706.	2.5	77
47	Interobserver reproducibility of histologic parameters of melanoma deposits in sentinel lymph nodes. Cancer, 2009, 115, 5026-5037.	4.1	75
48	Perivascular epithelioid tumours (PEComas) of the gynaecological tract. Journal of Clinical Pathology, 2015, 68, 418-426.	2.0	75
49	GNA11 Q209L Mouse Model Reveals RasGRP3 as an Essential Signaling Node in Uveal Melanoma. Cell Reports, 2018, 22, 2455-2468.	6.4	75
50	Evolving Roles of Histologic Evaluation and Molecular/Genomic Profiling in the Management of Endometrial Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 201-209.	4.9	75
51	Atypical fibroxanthoma and pleomorphic dermal sarcoma harbor frequent NOTCH1/2 and FAT1 mutations and similar DNA copy number alteration profiles. Modern Pathology, 2018, 31, 418-428.	5.5	75
52	Diagnosis of Metastatic Melanoma by Fine-Needle Biopsy. American Journal of Clinical Pathology, 2007, 127, 385-397.	0.7	72
53	BAP1 protein loss by immunohistochemistry: A potentially useful tool for prognostic prediction in patients with uveal melanoma. Pathology, 2013, 45, 651-656.	0.6	71
54	Sentinel Lymph Node Biopsy in Pediatric and Adolescent Cutaneous Melanoma Patients. Annals of Surgical Oncology, 2010, 17, 138-143.	1.5	68

#	Article	IF	CITATIONS
55	Lactate dehydrogenase 5 expression in melanoma increases with disease progression and is associated with expression of Bcl-XL and Mcl-1, but not Bcl-2 proteins. Modern Pathology, 2010, 23, 45-53.	5.5	68
56	Soâ€called "malignant blue nevus― Cancer, 2009, 115, 2949-2955.	4.1	66
57	DNA methylation and gene deletion analysis of brain metastases in melanoma patients identifies mutually exclusive molecular alterations. Neuro-Oncology, 2014, 16, 1499-1509.	1.2	65
58	Genetic Alterations and Personalized Medicine in Melanoma: Progress and Future Prospects. Journal of the National Cancer Institute, 2014, 106, djt435-djt435.	6.3	64
59	Functional RET G691S polymorphism in cutaneous malignant melanoma. Oncogene, 2009, 28, 3058-3068.	5.9	62
60	Prognostic Importance of the Extent of Ulceration in Patients With Clinically Localized Cutaneous Melanoma. Annals of Surgery, 2012, 255, 1165-1170.	4.2	62
61	Morphological and Immunohistochemical Reevaluation of Tumors Initially Diagnosed as Ovarian Endometrioid Carcinoma With Emphasis on High-grade Tumors. American Journal of Surgical Pathology, 2016, 40, 302-312.	3.7	61
62	Endocrine mucin-producing sweat gland carcinoma: report of a case and review of the literature. Journal of Cutaneous Pathology, 2006, 33, 812-816.	1.3	60
63	Osteolysis in Third-Generation Alumina Ceramic-on-Ceramic Hip Bearings With Severe Impingement and Titanium Metallosis. Journal of Arthroplasty, 2008, 23, 1240.e13-1240.e19.	3.1	60
64	Assessment of Copy Number Status of Chromosomes 6 and 11 by FISH Provides Independent Prognostic Information in Primary Melanoma. American Journal of Surgical Pathology, 2011, 35, 1146-1150.	3.7	60
65	GNAQ and GNA11 mutations in melanocytomas of the central nervous system. Acta Neuropathologica, 2012, 123, 457-459.	7.7	60
66	Increasing Tumor Thickness is Associated with Recurrence and Poorer Survival in Patients with Merkel Cell Carcinoma. Annals of Surgical Oncology, 2012, 19, 3325-3334.	1.5	59
67	Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical Sequencing. Clinical Cancer Research, 2020, 26, 3881-3888.	7.0	59
68	Cutaneous Head and Neck Squamous Cell Carcinoma with Regional Metastases: The Prognostic Importance of Soft Tissue Metastases and Extranodal Spread. Annals of Surgical Oncology, 2012, 19, 274-279.	1.5	57
69	Activating cysteinyl leukotriene receptor 2 (CYSLTR2) mutations in blue nevi. Modern Pathology, 2017, 30, 350-356.	5.5	56
70	Mycosis fungoides with large cell transformation: clinicopathological features and prognostic factors. Pathology, 2014, 46, 610-616.	0.6	55
71	Targeted next generation sequencing reveals unique mutation profile of primary melanocytic tumors of the central nervous system. Journal of Neuro-Oncology, 2016, 127, 435-444.	2.9	55
72	Cytologic Features of Epithelioid Hemangioendothelioma. American Journal of Clinical Pathology, 2011, 136, 739-746.	0.7	52

#	Article	lF	CITATIONS
73	Secondary Involvement of the Adnexa and Uterine Corpus by Carcinomas of the Uterine Cervix. International Journal of Gynecological Pathology, 2015, 34, 551-563.	1.4	52
74	OncoTree: A Cancer Classification System for Precision Oncology. JCO Clinical Cancer Informatics, 2021, 5, 221-230.	2.1	51
75	Clear cell atypical fibroxanthoma - report of a case with review of the literature. Journal of Cutaneous Pathology, 2006, 33, 343-348.	1.3	49
76	DIAGNOSIS AND MANAGEMENT OF SEBACEOUS CARCINOMA: AN AUSTRALIAN EXPERIENCE. ANZ Journal of Surgery, 2008, 78, 158-163.	0.7	49
77	MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome. BMC Cancer, 2010, 10, 497.	2.6	49
78	Cancer–testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate. European Journal of Cancer, 2011, 47, 460-469.	2.8	49
79	Clinicopathologic and Genomic Analysis of <i>TP53</i> Hutated Endometrial Carcinomas. Clinical Cancer Research, 2021, 27, 2613-2623.	7.0	49
80	The detection and significance of melanoma micrometastases in sentinel nodes. Surgical Oncology, 2008, 17, 165-174.	1.6	48
81	Histologically Ambiguous ("Borderlineâ€) Primary Cutaneous Melanocytic Tumors: Approaches to Patient Management Including the Roles of Molecular Testing and Sentinel Lymph Node Biopsy. Archives of Pathology and Laboratory Medicine, 2010, 134, 1770-1777.	2.5	47
82	Interobserver Variation in the Histopathologic Reporting of Key Prognostic Parameters, Particularly Clark Level, Affects Pathologic Staging of Primary Cutaneous Melanoma. Annals of Surgery, 2009, 249, 641-647.	4.2	45
83	Clinicopathologic Features of Incident and Subsequent Tumors in Patients with Multiple Primary Cutaneous Melanomas. Annals of Surgical Oncology, 2012, 19, 1024-1033.	1.5	45
84	Sentinel Lymph Nodes Containing Very Small (<0.1Âmm) Deposits of Metastatic Melanoma Cannot Be Safely Regarded as Tumor-Negative. Annals of Surgical Oncology, 2012, 19, 1089-1099.	1.5	45
85	Histological and genetic evidence for a variant of superficial spreading melanoma composed predominantly of large nests. Modern Pathology, 2012, 25, 838-845.	5.5	41
86	MAGI-2 scaffold protein is critical for kidney barrier function. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 14876-14881.	7.1	38
87	Frequent <i>GNAQ, GNA11</i> , and <i>EIF1AX</i> Mutations in Iris Melanoma., 2017, 58, 3464.		38
88	Assessment of SLX4 Mutations in Hereditary Breast Cancers. PLoS ONE, 2013, 8, e66961.	2.5	37
89	Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer. Oncotarget, 2015, 6, 44551-44562.	1.8	37
90	Outcomes following parotidectomy for metastatic squamous cell carcinoma with microscopic residual disease: Implications for facial nerve preservation. Head and Neck, 2009, 31, 21-27.	2.0	35

#	Article	IF	Citations
91	Factors Predicting Recurrence and Survival in Sentinel Lymph Node-Positive Melanoma Patients. Annals of Surgery, 2011, 253, 1155-1164.	4.2	34
92	Development of a risk stratification system to guide treatment for female germ cell tumors. Gynecologic Oncology, 2015, 138, 566-572.	1.4	34
93	Clinical and genetic analysis of melanomas arising in acral sites. European Journal of Cancer, 2019, 119, 66-76.	2.8	34
94	Ablation of B7-H3 but Not B7-H4 Results in Highly Increased Tumor Burden in a Murine Model of Spontaneous Prostate Cancer. Cancer Immunology Research, 2015, 3, 849-854.	3.4	32
95	Pathology and genetics of uveal melanoma. Pathology, 2013, 45, 18-27.	0.6	31
96	Primary calvarial meningioma. Journal of Clinical Neuroscience, 2007, 14, 1235-1239.	1.5	30
97	Clinical and Pathologic Factors Associated with Distant Metastasis and Survival in Patients with Thin Primary Cutaneous Melanoma. Annals of Surgical Oncology, 2012, 19, 1782-1789.	1.5	30
98	BAP1 expression in cutaneous melanoma: a pilot study. Pathology, 2013, 45, 606-609.	0.6	30
99	Genomic Profiling Aids Classification of Diagnostically Challenging Uterine Mesenchymal Tumors With Myomelanocytic Differentiation. American Journal of Surgical Pathology, 2021, 45, 77-92.	3.7	30
100	Number of primary melanomas is an independent predictor of survival in patients with metastatic melanoma. Cancer, 2012, 118, 4519-4529.	4.1	29
101	Lymphatic vessel density in primary melanomas predicts sentinel lymph node status and risk of metastasis. Histopathology, 2012, 61, 702-710.	2.9	29
102	Diagnostic Accuracy of Fine Needle Biopsy for Metastatic Melanoma and Its Implications for Patient Management. Annals of Surgical Oncology, 2008, 15, 323-332.	1.5	28
103	Integrated Genomic Classification of Melanocytic Tumors of the Central Nervous System Using Mutation Analysis, Copy Number Alterations, and DNA Methylation Profiling. Clinical Cancer Research, 2018, 24, 4494-4504.	7.0	28
104	PGR Gene Fusions Identify a Molecular Subset of Uterine Epithelioid Leiomyosarcoma With Rhabdoid Features. American Journal of Surgical Pathology, 2019, 43, 810-818.	3.7	28
105	Massively parallel sequencing analysis of 68 gastric-type cervical adenocarcinomas reveals mutations in cell cycle-related genes and potentially targetable mutations. Modern Pathology, 2021, 34, 1213-1225.	5.5	28
106	CD10 Immunohistochemical Staining in Urothelial Neoplasms. American Journal of Clinical Pathology, 2005, 124, 371-379.	0.7	26
107	Cytologic Features of Metastatic and Recurrent Melanoma in Patients with Primary Cutaneous Desmoplastic Melanoma. American Journal of Clinical Pathology, 2008, 130, 715-723.	0.7	24
108	Activating CYSLTR2 and PLCB4 Mutations in Primary Leptomeningeal Melanocytic Tumors. Journal of Investigative Dermatology, 2017, 137, 2033-2035.	0.7	24

#	Article	IF	CITATIONS
109	The roles of pathology in targeted therapy of women with gynecologic cancers. Gynecologic Oncology, 2018, 148, 213-221.	1.4	24
110	Disseminated mucormycosis and orbital ischaemia in combination immunosuppression with a tumour necrosis factor alpha inhibitor. Clinical and Experimental Ophthalmology, 2007, 35, 275-280.	2.6	22
111	<scp><i>BRAF</i>^{<i>V</i>}</scp> ^{<i>600E</i>} mutations and immunohistochemical expression of <scp>VE</scp> 1 protein in lowâ€grade serous neoplasms of the ovary. Histopathology, 2018, 73, 438-443.	2.9	22
112	Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes. Clinical Cancer Research, 2022, 28, 4947-4956.	7.0	22
113	Subcutaneous dermatofibrosarcoma protuberans in skin of the breast: may mimic a primary breast lesion. Pathology, 2007, 39, 446-448.	0.6	21
114	Usefulness of smears in intraâ€operative diagnosis of newly described entities of CNS. Neuropathology, 2009, 29, 641-648.	1.2	21
115	High molecular weight-melanoma-associated antigen as a biomarker of desmoplastic melanoma. Pigment Cell and Melanoma Research, 2010, 23, 137-140.	3.3	21
116	Rare De Novo Germline Copy-Number Variation in Testicular Cancer. American Journal of Human Genetics, 2012, 91, 379-383.	6.2	21
117	The genetic landscape of metaplastic breast cancers and uterine carcinosarcomas. Molecular Oncology, 2021, 15, 1024-1039.	4.6	21
118	Histopathological features of breast cancer in carriers of ATM gene variants. Histopathology, 2006, 49, 523-532.	2.9	20
119	Sentinel lymph node biopsy for melanoma: aspects of pathologic assessment. Future Oncology, 2008, 4, 535-551.	2.4	20
120	Merkel cell carcinoma with fibrosarcomatous differentiation. Pathology, 2008, 40, 314-316.	0.6	20
121	Fine-needle biopsy of metastatic melanoma: clinical use and new applications. Lancet Oncology, The, 2010, 11, 391-400.	10.7	20
122	Cytologic features of upper gynecologic tract adenocarcinomas exhibiting mesonephricâ€like differentiation. Cancer Cytopathology, 2019, 127, 521-528.	2.4	20
123	Clinical and pathological features of metastases of primary cutaneous desmoplastic melanoma. Histopathology, 2011, 58, 886-895.	2.9	19
124	Morphologic Features of Gastric-type Cervical Adenocarcinoma in Small Surgical and Cytology Specimens. International Journal of Gynecological Pathology, 2019, 38, 263-275.	1.4	18
125	Risk-based stratification of carcinomas concurrently involving the endometrium and ovary. Gynecologic Oncology, 2019, 152, 38-45.	1.4	18
126	Clinical relevance of melanoma micrometastases in sentinel nodes: too early to tell. Annals of Oncology, 2007, 18, 806-808.	1.2	17

#	Article	IF	Citations
127	The Pleura in Health and Disease. Seminars in Respiratory and Critical Care Medicine, 2010, 31, 649-673.	2.1	17
128	Melanocytic nevus with focal atypical epithelioid components (clonal nevus) is a combined nevus. Journal of the American Academy of Dermatology, 2007, 56, 889-890.	1.2	16
129	Deletion of $3p13-14$ locus spanning FOXP1 to SHQ1 cooperates with PTEN loss in prostate oncogenesis. Nature Communications, 2017, 8, 1081.	12.8	16
130	Genetic and molecular subtype heterogeneity in newly diagnosed early- and advanced-stage endometrial cancer. Gynecologic Oncology, 2021, 161, 535-544.	1.4	16
131	CD10 Immunohistochemical Staining in Urothelial Neoplasms. American Journal of Clinical Pathology, 2005, 124, 371-379.	0.7	16
132	TSC2-mutant uterine sarcomas with JAZF1-SUZ12 fusions demonstrate hybrid features of endometrial stromal sarcoma and PEComa and are responsive to mTOR inhibition. Modern Pathology, 2022, 35, 117-127.	5.5	16
133	Histiocytoid Change in Breast Carcinoma. Acta Cytologica, 2006, 50, 548-552.	1.3	15
134	Pigmented epithelioid melanocytoma: a recently described melanocytic tumour of low malignant potential. Pathology, 2010, 42, 284-286.	0.6	15
135	Digital papillary adenocarcinoma: a tumour that should be considered in the differential diagnosis of neoplasms involving the digits. Pathology, 2013, 45, 55-61.	0.6	15
136	Lymphoma occurring in patients with cutaneous melanoma. Journal of Clinical Pathology, 2010, 63, 777-781.	2.0	13
137	Melanotic schwannoma mimicking metastatic pigmented melanoma: a pitfall in cytological diagnosis. Pathology, 2010, 42, 287-289.	0.6	13
138	NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors. European Journal of Cancer, 2021, 159, 113-124.	2.8	13
139	TACI mutation with invasive polyclonal CD8+ T-cell lymphoproliferation in a patient with common variable immunodeficiency. Journal of Allergy and Clinical Immunology, 2006, 117, 870-877.	2.9	11
140	A 57-YEAR-OLD MAN WITH A DURAL-BASED PARIETAL LOBE TUMOR. Brain Pathology, 2007, 17, 460-463.	4.1	11
141	The Prognostic Significance of Isolated Immunohistochemically Positive Cells in Sentinel Lymph Nodes of Melanoma Patients. American Journal of Surgical Pathology, 2008, 32, 1106-1107.	3.7	11
142	Melanoma exhibiting cartilaginous differentiation. Histopathology, 2010, 56, 815-821.	2.9	11
143	Papillary tumour of the pineal region: cytological features and implications for intraoperative diagnosis. Pathology, 2010, 42, 474-479.	0.6	11
144	Approach to Lung Biopsies From Patients With Pneumothorax. Archives of Pathology and Laboratory Medicine, 2014, 138, 257-265.	2.5	11

#	Article	IF	CITATIONS
145	Somatic genetic alterations in synchronous and metachronous lowâ€grade serous tumours and highâ€grade carcinomas of the adnexa. Histopathology, 2019, 74, 638-650.	2.9	11
146	TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy. European Journal of Cancer, 2022, 161, 99-107.	2.8	10
147	Cytological features of melanoma in exfoliative fluid specimens. Journal of Clinical Pathology, 2009, 62, 638-643.	2.0	9
148	The Prognostic Value of Tumor Mitotic Rate and Other Clinicopathologic Factors in Patients with Locoregional Recurrences of Melanoma. Annals of Surgical Oncology, 2010, 17, 2992-2999.	1.5	9
149	Diagnosing a Primary Leptomeningeal Melanoma by Gene Mutation Signature. Journal of Investigative Dermatology, 2016, 136, 1526-1528.	0.7	9
150	Analysis of SDHD promoter mutations in various types of melanoma. Oncotarget, 2015, 6, 25868-25882.	1.8	9
151	Mucinous cyst exhibiting severe dysplasia in gastric heterotopic pancreas associated withe gastrointestinal stromal tumour. World Journal of Gastroenterology, 2007, 13, 5781.	3.3	9
152	Confirmation of Sentinel Lymph Node Identity by Analysis of Fine-Needle Biopsy Samples Using Inductively Coupled Plasma–Mass Spectrometry. Annals of Surgical Oncology, 2008, 15, 934-940.	1.5	8
153	Synchronous and metachronous malignancies in patients with melanoma: a clinicopathologic study highlighting the role of fine-needle biopsy cytology and potential diagnostic pitfalls. Melanoma Research, 2010, 20, 203-211.	1.2	8
154	Aberrant hypermethylation in primary tumours and sentinel lymph node metastases in paediatric patients with cutaneous melanoma. British Journal of Dermatology, 2012, 166, 1319-1326.	1.5	8
155	RNASeq analysis reveals biological processes governing the clinical behaviour of endometrioid and serous endometrial cancers. European Journal of Cancer, 2016, 64, 149-158.	2.8	8
156	Frequent Occurrence of NRAS and BRAF Mutations in Human Acral Naevi. Cancers, 2019, 11, 546.	3.7	8
157	Positron Lymphography via Intracervical ¹⁸ F-FDG Injection for Presurgical Lymphatic Mapping in Cervical and Endometrial Malignancies. Journal of Nuclear Medicine, 2020, 61, 1123-1130.	5.0	8
158	Can We Better Identify Thin Cutaneous Melanomas That are Likely to Metastasize and Cause Death?. Annals of Surgical Oncology, 2012, 19, 3310-3312.	1.5	7
159	Metaplastic Ossification in Mammary Fibroadenoma. Breast Journal, 2006, 12, 276-277.	1.0	6
160	Atypical fibroxanthoma: differential diagnosis from other sarcomatoid skin lesions. Diagnostic Histopathology, 2010, 16, 401-408.	0.4	6
161	Outcome of cervical intraepithelial neoplasia 2 diagnosed by punch biopsy in 131 women. Journal of Obstetrics and Gynaecology Research, 2011, 37, 754-761.	1.3	6
162	Fine-needle biopsy as a diagnostic technique for metastatic melanoma. Expert Opinion on Medical Diagnostics, 2008, 2, 1-10.	1.6	5

#	Article	IF	CITATIONS
163	Location of Melanoma Metastases in Sentinel Lymph Nodes: What are the Implications for Histologic Processing of Sentinel Lymph Nodes in Routine Practice?. American Journal of Surgical Pathology, 2010, 34, 127-129.	3.7	5
164	Molecular pathology as a diagnostic aid in difficult-to-classify melanocytic tumours with spitzoid morphology. European Journal of Cancer, 2021, 148, 340-347.	2.8	5
165	Cytologic features of sex cordâ€stromal tumors in women. Cancer Cytopathology, 2022, 130, 55-71.	2.4	5
166	Characterization, isolation, and in vitro culture of leptomeningeal fibroblasts. Journal of Neuroimmunology, 2021, 361, 577727.	2.3	5
167	Treatment of ovarian clear cell carcinoma with immune checkpoint blockade: a case series. International Journal of Gynecological Cancer, 2022, , ijgc-2022-003430.	2.5	5
168	MALIGNANT OPTIC GLIOMA PRESENTING AS AN ACUTE ANTERIOR OPTIC NEUROPATHY. Retinal Cases and Brief Reports, 2009, 3 , $156-160$.	0.6	4
169	Cytological features of transitional cell metaplasia of the lower female genital tract. Pathology, 2010, 42, 113-118.	0.6	4
170	Tumor-infiltrating lymphocytes and mitotic index in metastatic melanoma as predictors of patient survival. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, E46; author reply E47.	7.1	4
171	Concurrent involvement of thyroid gland by Wegener's granulomatosis and papillary thyroid carcinoma. Pathology, 2011, 43, 381-383.	0.6	4
172	Absence of loss of heterozygosity of BRCA1 in a renal tumor from a BRCA1 germline mutation carrier. Familial Cancer, 2013, 12, 125-127.	1.9	3
173	Re: van Poppelen etÂal.: Genetic background of iris melanomas and iris melanocytic tumors of uncertain malignant potential (Ophthalmology. 2018;125:904-912). Ophthalmology, 2018, 125, e78-e79.	5.2	3
174	Cytologic features of undifferentiated and dedifferentiated carcinomas of the endometrium. Cancer Cytopathology, 2021, 129, 121-131.	2.4	3
175	An Asymptomatic, Incidentally Discovered Pulmonary Tumor in a 41-Year-Old Woman. Archives of Pathology and Laboratory Medicine, 2005, 129, e191-e194.	2.5	3
176	Cutaneous Metastases. , 2010, , 637-650.		2
177	Completion lymph node dissection in melanoma patients with positive sentinel lymph nodes. European Journal of Surgical Oncology, 2013, 39, 1164-1165.	1.0	2
178	Multiple primary cutaneous melanomas: recent studies highlight features associated with more indolent behaviour. Pathology, 2013, 45, 1-3.	0.6	2
179	Genetic analysis of a morphologically heterogeneous ovarian endometrioid carcinoma. Histopathology, 2017, 71, 480-487.	2.9	2
180	A guided tour of selected issues pertaining to metastatic carcinomas involving or originating from the gynecologic tract. Seminars in Diagnostic Pathology, 2018, 35, 95-107.	1.5	2

#	Article	IF	CITATIONS
181	Transducin-Like Enhancer of Split 3 (TLE3) Expression Is Associated with Taxane Sensitivity in Nonserous Ovarian Carcinoma in a Three-Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 680-688.	2.5	2
182	Molecular Pathology and Genomics of Melanoma. , 2019, , 1-42.		2
183	Can Histologic Parameters of Melanoma Metastases in Sentinel Lymph Nodes Reliably Select Patients Who Can Be Safely Spared Completion Lymph Node Dissection?. Annals of Surgery, 2010, 251, 1188-1189.	4.2	1
184	Molecular Pathology and Genomics of Melanoma. , 2020, , 381-422.		1
185	Female germ cell tumors (GCT): The Memorial Sloan Kettering Cancer Center (MSKCC) experience Journal of Clinical Oncology, 2014, 32, 5539-5539.	1.6	1
186	TCR Repertoires in Graft-Versus-Host-Disease (GVHD)-Target Tissues Reveals Tissue Specificity of the Alloimmune Response. Blood, 2020, 136, 21-23.	1.4	1
187	Florid (Floral) Synovitis. International Journal of Surgical Pathology, 2006, 14, 146-146.	0.8	O
188	Fine Needle Aspiration Cytology. Pathology, 2007, 39, 191.	0.6	0
189	Genetic alterations in uveal melanoma. Expert Review of Ophthalmology, 2011, 6, 129-132.	0.6	O
190	Reply to I. Satzger et al. Journal of Clinical Oncology, 2011, 29, e316-e317.	1.6	O
191	Response. Journal of the National Cancer Institute, 2015, 107, djv051-djv051.	6.3	O
192	A pragmatic approach to carcinomas concurrently involving the endometrium and ovary. Gynecologic Oncology Reports, 2019, 27, 74.	0.6	0
193	Melanocytic Proliferations of the Eye. , 2014, , 509-527.		O
194	Melanocytic Neoplasms of the Mucosa. , 2014, , 489-508.		0
195	Abstract 1537: 3p13-14FOXP1-SHQ1deletion spanning multiple potential tumor suppressor genes cooperates withPTENloss in cancer. , 2017, , .		O